Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.580 -0.380 (-6.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... 
Via Benzinga
Vir Biotechnology's Earnings Outlook
Via Benzinga
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Final draft guidance based on cost effectiveness evaluation of sotrovimab 
From Vir Biotechnology, Inc.
Via GlobeNewswire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Analyst Expectations for Vir Biotechnology's Future
Via Benzinga
2 Fast-Growing Healthcare Stocks to Buy and Hold
The innovative companies have made great gains in a short period of time. 
Via The Motley Fool
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  
Via Benzinga
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,... 
Via Benzinga
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
From Vir Biotechnology, Inc.
Via GlobeNewswire
Insiders Selling Meta Platforms And 3 Other Stocks
The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
From Vir Biotechnology, Inc.
Via GlobeNewswire
2 Stocks That Could Turn $100 Into $1,000 by 2028
These growth stocks have substantial tailwinds. 
Via The Motley Fool
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 – 
From Vir Biotechnology, Inc.
Via GlobeNewswire
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS